NCT05442190
Topical SGX302 for Mild-to-Moderate Psoriasis
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 8 versions: 8 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Results posted: Nov 17, 2026
- Eligibility criteria expanded, about 7 words
- Primary endpoint revised
- Secondary endpoints: 3 to 2
- Minor Interventions: Hypericin (Drug), Placebo (Drug) to Hypericin (Drug)v7
Minor Trial status: Recruiting to Completedv6 Show 4 more changesShow less
- Enrollment target: estimated 47 to confirmed 15
- Primary completion date changed from estimate of Oct 2025 to Oct 22, 2025
- Study completion date changed from estimate of Dec 2025 to Nov 17, 2025
- Site details revised
- Minor Primary completion date: Apr 2025 to Oct 2025
- Study completion date: Jun 2025 to Dec 2025
- Minor Enrollment target: 42 to 47
- Study arms: 2 to 3
Show 2 earlier versionsHide 2 earlier versions
- Notable Primary completion date: Oct 2023 to Apr 2025
- Study completion date: Dec 2023 to Jun 2025
- Notable Trial status: Not Yet Recruiting to Recruiting
- Enrollment target: 32 to 42
- Study sites: 0 to 1
- Start date changed from estimate of Dec 2022 to Dec 14, 2022
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (2)
Arms and interventions
SGX302 (0.25 % hypericin) ointment will be applied to lesions and treated with visible light 24±6 hours later starting at 5 J/cm\^2 with a gradual escalation of light therapy up to 25 J/cm\^2. Drug application/light session will be done twice a week (at least 2 calendar days apart) for 18 weeks.
SGX302 (0.25 % hypericin) ointment will be applied to lesions and treated with visible light 24±6 hours later starting at 5 J/cm\^2 with a faster escalation of light therapy up to 25 J/cm\^2. Drug application/light session will be done twice a week (at least 2 calendar days apart) for 18 weeks.
SGX302 (0.25 % hypericin) gel will be applied to lesions and treated with visible light 24±6 hours later starting at 5 J/cm\^2 with a faster escalation of light therapy up to 40 J/cm\^2. Drug application/light session will be done twice a week (at least 2 calendar days apart) for 18 weeks.
Drugs: Hypericin
Sites
1 site in 1 country
- Therapeutics Clinical ResearchSan Diego, California, United States